Okyo pharma limitedOKYO.US Overview

US StockHealthcare

(No presentation for OKYO)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

OKYO Overall Performance

OKYO AI Analysis & Strategy

OKYO Recent Performance

1.90%

Okyo pharma limited

1.30%

Avg of Sector

0.61%

S&P500

OKYO PowerScanner

OKYO Key Information

OKYO Valuation Metrics

OKYO Earnings Table

OKYO Profile

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.